September 2019: Recommendation 1.7.4 was amended to indicate that an electrocardiogram is not needed before starting stimulants, atomoxetine or guanfacine if cardiovascular history and examination are normal and the person is not on medicine that poses an increased cardiovascular risk. The corresponding rationale section was also updated to reflect this change. This recommendation is marked [2018, amended 2019].
April 2018: Following publication, some amendments were made to recommendations 1.5.10, 1.5.12, 1.5.13, 1.7.4, 1.7.7 and 1.8.14 and the related rationale and impact sections to clarify their meaning. Information about the marketing authorisation for methylphenidate was also added to recommendation 1.7.11.
March 2018: This guideline updates and replaces NICE guideline CG72 (published September 2008).
New recommendations have been added on recognition, information and support, managing attention deficit hyperactivity disorder (ADHD; including non-pharmacological treatment), medication, follow‑up and monitoring, adherence, and review of medication and discontinuation.
These are marked as .
We also made some changes without an evidence review:
We have clarified the names of services.
We have added cross-references to NICE guidelines on transition from children's to adults' services and antisocial behaviour and conduct disorders in children and young people.
We have clarified that any support for parents and carers before a formal diagnosis should be group-based and ADHD focused.
We have made changes to reflect the most recent version of DSM.
Minor changes since publication
January 2023: We have updated recommendation 1.2.1 because ADHD is now recognised as a neurodevelopmental disorder and recommendation 1.3.3 to update ICD-10 to ICD-11.
March 2022: We clarified that recommendation 1.7.22 only covers preparations of methylphenidate.